6533b823fe1ef96bd127e30c

RESEARCH PRODUCT

Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study

subject

description

BackgroundSodium-glucose linked transporter 2 inhibition recently emerged as a promising therapy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to evaluate the short-term effects of empagliflozin on maximal exercise capacity in these patients. HypothesisWe postulate tretament with empagliflozin may improve functional capacity in patients with T2DM and established HF. MethodsNineteen T2DM patients with symptomatic HF were prospectively included and underwent cardiopulmonary exercise testing before and 30days after initiation of empagliflozin therapy. A mixed-effects model for repeated measures was used. ResultsMedian patient age was 72years (interquartile range, 60-79years); 42.1% were in New York Heart Association class III. Baseline mean ( SD) peak oxygen consumption (peak VO2) was 10.9 +/- 4.0mL/min/kg. Peak VO2 increased significantly at 30days (: +1.21 [0.66 to 1.76] mL/min/kg; P<0.001). A significant improvement in ventilatory efficiency during exercise, 6-minute walking distance, and quality of life, and a reduction in antigen carbohydrate 125, were also found. Estimated glomerular filtration rate and natriuretic peptides did not significantly change. ConclusionsIn this pilot study, empagliflozin was associated with 1-month improvement in exercise capacity in T2DM patients with symptomatic HF. This beneficial effect was also found for other surrogates of severity.